The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
Open accessAbstract
BACKGROUND: Hematopoietic stem-cell transplantation (HSCT) is a potentially lifesaving therapy for several blood cancers and other diseases. For patients without a suitable related HLA-matched donor, unrelated-donor registries of adult volunteers and banked umbilical cord-blood units, such as the Be the Match Registry operated by the National Marrow Donor Program (NMDP), provide potential sources of donors. Our goal in the present study was to measure the likelihood of finding a suitable donor in the U.S. registry. METHODS: Using human HLA data from the NMDP donor and cord-blood-unit registry, we built population-based genetic models for 21 U.S. racial and ethnic groups to predict the likelihood of identifying a suitable donor (either an adult donor or a cord-blood unit) for patients in each group. The models incorporated the degree of HLA matching, adult-donor availability (i.e., ability to donate), and cord-blood-unit cell dose. RESULTS: Our models indicated that most candidates for HSCT will have a suitable (HLA-matched or minimally mismatched) adult donor. However, many patients will not have an optimal adult donor--that is, a donor who is matched at high resolution at HLA-A, HLA-B, HLA-C, and HLA-DRB1. The likelihood of finding an optimal donor varies among racial and ethnic groups, with the highest probability among whites of European descent, at 75%, and the lowest probability among blacks of South or Central American descent, at 16%. Likelihoods for other groups are intermediate. Few patients will have an optimal cord-blood unit--that is, one matched at the antigen level at HLA-A and HLA-B and matched at high resolution at HLA-DRB1. However, cord-blood units mismatched at one or two HLA loci are available for almost all patients younger than 20 years of age and for more than 80% of patients 20 years of age or older, regardless of racial and ethnic background. CONCLUSIONS: Most patients likely to benefit from HSCT will have a donor. Public investment in donor recruitment and cord-blood banks has expanded access to HSCT. (Funded by the Office of Naval Research, Department of the Navy, and the Health Resources and Services Administration, Department of Health and Human Services.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.
(1995) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a040269 · Cited by 1,950
Lee, S. J., Klein, J., Haagenson, M., Baxter-Lowe, L. A., Confer, D. L., Eapen, M., Fernandez-Vina, M., Flomenberg, N., Horowitz, M., Hurley, C. K., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097386 · Cited by 1,255
Self-citationLaughlin, M. J., Eapen, M., Rubinstein, P., Wagner, J. E., Zhang, M.-J., Champlin, R. E., Stevens, C., Barker, J. N., Gale, R. P., Lazarus, H. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041276 · Cited by 1,062
Self-citationKurtzberg, J., Laughlin, M., Graham, M. L., Smith, C., Olson, J. F., Halperin, E. C., Ciocci, G., Carrier, C., Stevens, C. E., & Rubinstein, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607183350303 · Cited by 1,024
Eapen, M., Rubinstein, P., Zhang, M.-J., Stevens, C., Kurtzberg, J., Scaradavou, A., Loberiza, F. R., Champlin, R. E., Klein, J. P., Horowitz, M. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60915-5 · Cited by 799
Self-citationEapen, M., Rocha, V., Sanz, G., Scaradavou, A., Zhang, M.-J., Arcese, W., Sirvent, A., Champlin, R. E., Chao, N., Gee, A. P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70127-3 · Cited by 586
Self-citationBrunstein, C. G., Barker, J. N., Weisdorf, D. J., DeFor, T. E., Miller, J. S., Blazar, B. R., McGlave, P. B., & Wagner, J. E. (2007) · Blood · doi:10.1182/blood-2007-04-067215 · Cited by 501
Gragert, L., Madbouly, A., Freeman, J., & Maiers, M. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.06.025 · Cited by 421
Self-citation
Cited by
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Ciurea, S. O., Zhang, M.-J., Bacigalupo, A. A., Bashey, A., Appelbaum, F. R., Aljitawi, O. S., Armand, P., Antin, J. H., Chen, J., Devine, S. M., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639831 · Cited by 662
Self-citationPyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal
Fares, I., Chagraoui, J., Gareau, Y., Gingras, S., Ruel, R., Mayotte, N., Csaszar, E., Knapp, D. J. H. F., Miller, P., Ngom, M., et al. (2014) · Science · doi:10.1126/science.1256337 · Cited by 565
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Milano, F., Gooley, T., Wood, B., Woolfrey, A., Flowers, M. E., Doney, K., Witherspoon, R., Mielcarek, M., Deeg, J. H., Sorror, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602074 · Cited by 443
Kollman, C., Spellman, S. R., Zhang, M.-J., Hassebroek, A., Anasetti, C., Antin, J. H., Champlin, R. E., Confer, D. L., DiPersio, J. F., Fernandez-Viña, M., et al. (2016) · Blood · doi:10.1182/blood-2015-08-663823 · Cited by 365
Self-citationHematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
Modern approaches to HLA-haploidentical blood or marrow transplantation
Kanakry, C. G., Fuchs, E. J., & Luznik, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.128 · Cited by 330
Dehn, J., Spellman, S., Hurley, C. K., Shaw, B. E., Barker, J. N., Burns, L. J., Confer, D. L., Eapen, M., Fernandez-Vina, M., Hartzman, R., et al. (2019) · Blood · doi:10.1182/blood.2019001212 · Cited by 323
Self-citationXu, L., Chen, H., Chen, J., Han, M., Huang, H., Lai, Y., Liu, D., Liu, Q., Liu, T., Jiang, M., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0564-x · Cited by 294
Wachsmuth, L. P., Patterson, M. T., Eckhaus, M. A., Venzon, D. J., Gress, R. E., & Kanakry, C. G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124218 · Cited by 292
NK cells and ILCs in tumor immunotherapy
Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 270
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 268
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Watkins, B., Qayed, M., McCracken, C., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Sinclair, S., Furlan, S., Bosinger, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01086 · Cited by 264
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives
Henig, I., & Zuckerman, T. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10162 · Cited by 209
Eapen, M., Brazauskas, R., Walters, M. C., Bernaudin, F., Bo-Subait, K., Fitzhugh, C. D., Hankins, J. S., Kanter, J., Meerpohl, J. J., Bolaños-Meade, J., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30154-1 · Cited by 206
Self-citationChronic Granulomatous Disease: a Comprehensive Review
Yu, H.-H., Yang, Y.-H., & Chiang, B.-L. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08800-x · Cited by 197
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Gibson, C. J., Kim, H. T., Zhao, L., Murdock, H. M., Hambley, B., Ogata, A., Madero-Marroquin, R., Wang, S., Green, L., Fleharty, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02286 · Cited by 168
Breda, L., Motta, I., Lourenco, S., Gemmo, C., Deng, W., Rupon, J. W., Abdulmalik, O. Y., Manwani, D., Blobel, G. A., & Rivella, S. (2016) · Blood · doi:10.1182/blood-2016-01-691089 · Cited by 83
Brendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62
Fabricius, W. A., & Ramanathan, M. (2016) · Advances in Hematology · doi:10.1155/2016/5726132 · Cited by 46
Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?
Leonard, A., Tisdale, J., & Abraham, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16437 · Cited by 45
Metadata
- Authors
- Gragert, L., Eapen, M., Williams, E., Freeman, J., Spellman, S., Baitty, R., Hartzman, R., Rizzo, J. D., Horowitz, M., Confer, D., & Maiers, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 339-348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1978164777
- Cited by
- 1,103
- References
- 20
- FWCI
- 50.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.